Central Nervous System Treatment Market Updates

Global Central Nervous System Treatment Market size was valued at USD 128.29 billion in 2023 and is poised to grow from USD 136.37 billion in 2024 to USD 222.33 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032). 

Mergers, acquisitions, and partnerships are among the important market trends that are present. Major players in the market who are developing novel therapeutics for the treatment of disorders of the central nervous system have agreements with rival firms for distribution and research and development. For instance, Biogen and Sangamo Therapeutics reached an agreement to develop novel gene therapy medications for a range of neurological illnesses. The prospects of the CNS therapeutics market would be greatly improved by strategic actions implemented by leading businesses. 'Biogen Inc. (United States) ', 'Johnson & Johnson (United States) ', 'Novartis AG (Switzerland) ', 'UCB S.A. (Belgium) ', 'Takeda Pharmaceutical Company Ltd. (Japan) ', 'Pfizer Inc. (United States) ', 'Roche Holding AG (Switzerland) ', 'Sanofi S.A. (France) ', 'Eli Lilly and Company (United States) ', 'Otsuka Holdings Co., Ltd. (Japan) ', 'Lundbeck A/S (Denmark) ', 'GlaxoSmithKline plc (GSK) (United Kingdom) ', 'AstraZeneca plc (United Kingdom) ', 'Merck & Co., Inc. (United States) ', 'Bristol-Myers Squibb Company (United States) ', 'Amgen Inc. (United States) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'AbbVie Inc. (United States) ', 'Allergan plc (Ireland) ', 'Shionogi & Co., Ltd. (Japan) '

The frequency and incidence of neurological illnesses, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease, among others, are rapidly rising globally. In the upcoming years, the market's growth is expected to be significantly impacted by this increase. On the other side, countries with an increasing geriatric population are also experiencing an upsurge in the prevalence of Alzheimer's disease. For instance, the Alzheimer's Association estimates that more than five million people worldwide already suffer from Alzheimer's disease, and that figure is expected to increase to 14 million by the year 2050. 

Improvements in Diagnosis and Therapeutics: The development of the therapeutics market for the central nervous system is being fuelled by improvements in diagnostics, therapies, and drug discovery approaches. 

By holding the greatest revenue share of 49.3%, North America dominated the market for CNS therapeutics. The presence of large corporations and efforts made by major medical organizations to create novel medicines for various central nervous system ailments are the factors anticipated to enhance the total market share.